bionlp-st-ge-2016-spacy-parsed Home  

PMC:1064895 / 2667-2921 JSONTXT 24 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T3896 0-3 DT denotes The
T3897 4-13 JJ denotes favorable
T3898 14-22 JJ denotes clinical
T3899 23-31 NNS denotes benefits
T3900 32-40 VBN denotes obtained
T3901 41-45 IN denotes with
T3902 46-56 NNS denotes inhibitors
T3903 57-59 IN denotes of
T3904 60-65 NN denotes tumor
T3905 66-74 NN denotes necrosis
T3906 75-81 NN denotes factor
T3907 82-83 -LRB- denotes (
T3908 83-86 NNP denotes TNF
T3909 86-87 -RRB- denotes )
T3910 87-88 : denotes -
T3911 88-89 VBN denotes α
T3912 89-90 -RRB- denotes )
T3913 91-94 CC denotes and
T3914 95-106 NN denotes interleukin
T3915 107-108 -LRB- denotes (
T3916 108-110 NNP denotes IL
T3917 110-111 -RRB- denotes )
T3918 111-113 CD denotes -1
T3919 114-121 VBP denotes suggest
T3920 122-126 IN denotes that
T3921 127-130 DT denotes the
T3922 131-139 NN denotes blockade
T3923 140-142 IN denotes of
T3924 143-146 JJ denotes key
T3925 147-159 JJ denotes inflammatory
T3926 160-169 NNS denotes cytokines
T3927 170-173 VBZ denotes has
T3928 174-178 VBN denotes been
T3929 179-182 DT denotes the
T3930 183-192 JJ denotes important
T3931 193-198 NN denotes issue
T3932 199-201 IN denotes in
T3933 202-205 DT denotes the
T3934 206-217 NN denotes development
T3935 218-220 IN denotes of
T3936 221-224 JJ denotes new
T3937 225-236 JJ denotes therapeutic
T3938 237-249 NNS denotes applications
T3939 250-251 JJ denotes [
T3940 251-252 CD denotes 2
T3941 252-253 NN denotes ]
T3942 253-254 . denotes .
R1947 T3896 T3899 det The,benefits
R1951 T3897 T3899 amod favorable,benefits
R1955 T3898 T3899 amod clinical,benefits
R1958 T3899 T3911 nsubj benefits,α
R1962 T3900 T3899 acl obtained,benefits
R1966 T3901 T3900 prep with,obtained
R1969 T3902 T3901 pobj inhibitors,with
R1973 T3903 T3902 prep of,inhibitors
R1977 T3904 T3905 compound tumor,necrosis
R1983 T3905 T3906 compound necrosis,factor
R1984 T3906 T3903 pobj factor,of
R1985 T3907 T3908 punct (,TNF
R1988 T3908 T3906 appos TNF,factor
R1990 T3909 T3900 punct ),obtained
R1993 T3910 T3899 punct -,benefits
R1997 T3911 T3911 ROOT α,α
R2000 T3912 T3911 punct ),α
R2004 T3913 T3911 cc and,α
R2008 T3914 T3919 nsubj interleukin,suggest
R2012 T3915 T3916 punct (,IL
R2015 T3916 T3914 appos IL,interleukin
R2019 T3917 T3918 punct ),-1
R2023 T3918 T3919 nsubj -1,suggest
R2026 T3919 T3911 conj suggest,α
R2033 T3920 T3928 mark that,been
R2037 T3921 T3922 det the,blockade
R2041 T3922 T3928 nsubj blockade,been
R2045 T3923 T3922 prep of,blockade
R2048 T3924 T3926 amod key,cytokines
R2052 T3925 T3926 amod inflammatory,cytokines
R2056 T3926 T3923 pobj cytokines,of
R2060 T3927 T3928 aux has,been
R2064 T3928 T3919 ccomp been,suggest
R2068 T3929 T3931 det the,issue
R2071 T3930 T3931 amod important,issue
R2075 T3931 T3928 attr issue,been
R2079 T3932 T3931 prep in,issue
R2081 T3933 T3934 det the,development
R2084 T3934 T3932 pobj development,in
R2087 T3935 T3934 prep of,development
R2091 T3936 T3938 amod new,applications
R2095 T3937 T3938 amod therapeutic,applications
R2097 T3938 T3935 pobj applications,of
R2100 T3939 T3941 amod [,]
R2104 T3940 T3941 nummod 2,]
R2107 T3941 T3931 conj ],issue
R2111 T3942 T3919 punct .,suggest